• Genomics leader relocates to an expanded footprint in Sunnyvale
• New location enables customer continuity and provides increased innovation space to drive growth in MRD and MCED markets
• Newly appointed Chief Technology Officer joins IDT as part of strategic move

Global genomics leader Integrated DNA Technologies (IDT)  announced the relocation of its original Bay Area site from Redwood City to Sunnyvale. The strategic move marks an investment in IDT’s expansion in the Bay Area and continued commitment to serving the vibrant San Francisco biotechnology community. It is also part of IDT’s broader strategy to expand its research, development, and innovation capabilities to support market growth in precision oncology, including the minimal residual disease (MRD) and multi-cancer early detection (MCED) markets.

Fostering innovation and collaboration

The 12,000-square-foot facility in Sunnyvale will feature state-of-the-art laboratory and office space designed to foster greater innovation, enhance research and development initiatives, and deepen collaboration opportunities with partners. Planned improvements in 2026 will further expand the space to support future growth.

“This relocation marks a significant milestone in our continued investments to scale our R&D and innovation platforms,” said Ajay Gannerkote, president, IDT. “Our expanded footprint will ensure customer continuity, strengthen partnerships and create new opportunities for collaboration as we advance cutting-edge solutions in MRD and MCED.”

Strengthening leadership for the next era of innovation

As part of this strategic move, IDT has appointed Steven Henck, PhD, as Chief Technology Officer—a homecoming for a next generation sequencing (NGS) pioneer whose career has shaped the future of sequencing technologies. In this new capacity, Henck will engineer IDT’s transformative synthesis technologies and steer the company in driving the next wave of NGS and molecular biology innovation. Since joining IDT in 2019 as vice president of R&D, Henck most recently advanced to the CTO office at Danaher Life Sciences Omics Solutions Group as NGS Fellow, leveraging his nearly 30-year track record to drive high-throughput platforms for drug discovery, protein engineering, and antibody development.

Innovation nexus transition 

Last year, IDT installed an innovation nexus, which will also transition to the Sunnyvale location. The innovation nexus serves as a collaboration center that enables IDT to innovate with regional customers, forge strategic partnerships, and drive R&D initiatives with leading-edge biotechnology companies. The innovation nexus also enables the transformation of IDT’s technical capabilities, building on its legacy portfolio and proven expertise in oligo synthesis technologies. This includes acquiring emerging and transformative synthesis technologies ranging from novel chemistries, enzymatic synthesis, and alternative platforms, to drive market growth in precision oncology research through advanced next generation sequencing applications and high-throughput approaches.

The new Sunnyvale site, located on E. Caribbean Dr. on the Cepheid campus, another Danaher Company, positions IDT closer to key industry partners and joint ventures, and will serve as a hub for scientific excellence and strategic alliance. IDT’s Redwood City office closed at the end of 2025.